Peanut Allergy Desensitization Via a Convenient Fully-Functional Toothpaste Paradigm with Abhit Singh, MD, MHA

Abhit Singh and Adam Torres discuss Intrommune Therapeutics.

Subscribe: iTunes / Spotify / Stitcher / RSS

Apply to be a guest on our podcast here

Show Notes:

Abhit Singh, MD, MHA , VP Medical Affairs, Ex- Chief Regulatory Officer at Intrommune Therapeutics

Intrommune Therapeutics is looking to bring new hope to those suffering from peanut allergies. In this episode,  Adam Torres and Abhit Singh, MD, MHA , VP Medical Affairs, Ex- Chief Regulatory Officer at Intrommune Therapeutics, explore the trajectory of Intrommune Therapeutics and the future of it’s products.

About Abhit Singh

Dynamic Global Physician Leader, Renegade Thinker and Speaker – specializing in the Medical Advisory, Transactional and Transformational Management of Biotech and Healthcare organizations. Expert in spearheading cross-functional teams in a matrix ecosystem towards realizing strategic project goals. Have a talent for ensuring alignment, synergy, and synchronicity towards an organization’s mission, values, and vision.

About Intrommune Therapeutics

Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY. Intrommune is developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer fro​m peanut allergy.

Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.

This image has an empty alt attribute; its file name is Final-VIP-UPGRADE-Banner-1-1024x162.png